Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Non-GAAP R&D expenses as % of total revenues by Quarter
Non-GAAP R&D expenses as % of total revenues (%) (%)
Gilead Sciences Non-GAAP R&D expenses as % of total revenues: 22.6% in Q2 2026, up 1.5 pts from a year earlier.
Where the Q2 2026 figure comes from
“|| Research and development expenses as a % of revenues | 22.6 | % | 21.1 | % | 21.2 | % | 20.9 | %”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 8-K Non-GAAP Financial Information.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Non-GAAP R&D expenses as % of total revenues (%), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd-nongaap-pct-rev
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.